0 CHECKOUT

Cholera - Pipeline Review, H2 2015

  • ID: 3404562
  • August 2015
  • 47 pages
  • Global Markets Direct
1 of 4

Cholera - Pipeline Review, H2 2015

Summary

The report ‘Cholera - Pipeline Review, H2 2015’, provides an overview of the Cholera’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cholera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cholera and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Cholera Overview

Therapeutics Development

Pipeline Products for Cholera - Overview

Pipeline Products for Cholera - Comparative Analysis

Cholera - Therapeutics under Development by Companies

Cholera - Therapeutics under Investigation by Universities/Institutes

Cholera - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Cholera - Products under Development by Companies

Cholera - Products under Investigation by Universities/Institutes

Cholera - Companies Involved in Therapeutics Development

Akthelia pharmaceuticals ehf

Beijing Minhai Biotechnology Co., Ltd

PaxVax

Cholera - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AKT-10082 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cholera (trivalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

crofelemer DR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IMSUTMR-1501 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PXVX-0200 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cholera - Recent Pipeline Updates

Cholera - Dormant Projects

Cholera - Discontinued Products

Cholera - Product Development Milestones

Featured News & Press Releases

Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix

Dec 08, 2014: PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial

Sep 30, 2014: Specialty Vaccine Company PaxVax to Present at 13th Annual BIO Investor Forum

Jul 01, 2014: Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study

May 27, 2014: Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference

Jan 09, 2014: PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned

Sep 06, 2013: PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine

Nov 14, 2012: PaxVax Presents Phase I Clinical Trial Results Of Single-dose Cholera Vaccine At 2012 ASTMH Annual Meeting

Mar 19, 2012: FDA Accepts PaxVax’s IND For Single-Dose Oral Cholera Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cholera, H2 2015

Number of Products under Development for Cholera - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Cholera - Pipeline by Akthelia pharmaceuticals ehf, H2 2015

Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015

Cholera - Pipeline by PaxVax, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Cholera Therapeutics - Recent Pipeline Updates, H2 2015

Cholera - Dormant Projects, H2 2015

Cholera - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Cholera, H2 2015

Number of Products under Development for Cholera - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Akthelia pharmaceuticals ehf
Beijing Minhai Biotechnology Co., Ltd
PaxVax

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Cache

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.